Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jocs.15856 | DOI Listing |
Hormones (Athens)
December 2024
Hormones Editor-in-Chief, Hormones, Athens, Greece.
Expert Rev Anticancer Ther
December 2021
IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Oncologia Medica del Sistema Nervoso, Bologna, Italy.
Introduction: The field of cancer immunotherapy has achieved great advancements through the application of genetically engineered T cells with chimeric antigen receptors (CAR), that have shown exciting success in eradicating hematologic malignancies and have proved to be safe with promising early signs of antitumoral activity in the treatment of glioblastoma (GBM).
Areas Covered: We discuss the use of CAR T cells in GBM, focusing on limitations and obstacles to advancement, mostly related to toxicities, hostile tumor microenvironment, limited CAR T cells infiltration and persistence, target antigen loss/heterogeneity and inadequate trafficking. Furthermore, we introduce the refined strategies aimed at strengthening CAR T activity and offer insights in to novel immunotherapeutic approaches, such as the potential use of CAR NK or CAR M to optimize anti-tumor effects for GBM management.
J Card Surg
October 2021
International School of Cardiac Surgery, Ettore Majorana Foundation and Center for Scientific Culture, Erice, Italy.
Future Microbiol
September 2017
Department of Infectious Diseases, Catholic University of Rome, Italy.
World Neurosurg
February 2015
Department of Neurosciences & Reproductive and Odontostomatological Sciences, Division of Neurosurgery, Università degli Studi di Napoli Federico II, Naples, Italy. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!